Skip to main content

CASE REPORT article

Front. Immunol.
Sec. Alloimmunity and Transplantation
Volume 15 - 2024 | doi: 10.3389/fimmu.2024.1444010
This article is part of the Research Topic Cellular Therapies and Outpatient Care: from the Basics to Clinics View all 13 articles

Case Report: Treatment of Parkinsonism Secondary to Ciltacabtagene Autoleucel Using a Combination Dopaminergic Regimen

Provisionally accepted
Raya Aliakbar Raya Aliakbar 1Olga Manouvakhova Olga Manouvakhova 1Cindy Wong Cindy Wong 1Myo Htut Myo Htut 2Johannes Pulst-Korenberg Johannes Pulst-Korenberg 1Murali Janakiram Murali Janakiram 2Michael Rosenzweig Michael Rosenzweig 2Scott Goldsmith Scott Goldsmith 2*Xenos Mason Xenos Mason 1*
  • 1 Keck School of Medicine, University of Southern California, Los Angeles, United States
  • 2 Division of Multiple Myeloma, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, United States

The final, formatted version of the article will be published soon.

    We report on a patient with Ciltacabtagene autoleucel-induced movement and neurocognitive toxicity, which was refractory to immunosuppression but responsive to combination dopaminergic therapy (carbidopa/levodopa, ropinirole, amantadine). Response was seen upon both initial treatment and rechallenge after unintended withdrawal. This is the first report of successful symptomatic treatment of this well-described neurotoxic syndrome.

    Keywords: ciltacabtagene autoleucel, Movement and Neurocognitive Toxicity, parkinsonism, car-t, Multiple Myeloma

    Received: 04 Jun 2024; Accepted: 29 Aug 2024.

    Copyright: © 2024 Aliakbar, Manouvakhova, Wong, Htut, Pulst-Korenberg, Janakiram, Rosenzweig, Goldsmith and Mason. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Scott Goldsmith, Division of Multiple Myeloma, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, United States
    Xenos Mason, Keck School of Medicine, University of Southern California, Los Angeles, United States

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.